Immunotherapy with levamisole. Early decrease of cAMP levels in lymphocytes from treated cancer patients

U. H. Lewinski, G. M. Mavligit, W. J. Thompson, Evan M Hersh, R. A. Ortez

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Lymphocyte cyclic nucleotide content was studied before and after Levamisole administration to cancer patients. Twelve patients with disseminated cancer received 100 mg/m 2 on two consecutive days; nine comparable patients with disseminated cancer served as controls. Endogeneous cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) were measured in lymphocytes before, 24, and 48 hours after ingestion of the first dose of Levamisole. A statistically significant decline in lymphocyte cAMP level was observed after drug administration and no significant changes were noted in cGMP levels. Further studies will be necessary to correlate this biochemicl change in cyclic nucleotides with modulation of the functional level of cellular immune mechanisms.

Original languageEnglish (US)
Pages (from-to)1280-1283
Number of pages4
JournalCancer
Volume44
Issue number4
DOIs
StatePublished - 1979
Externally publishedYes

Fingerprint

Levamisole
Cyclic AMP
Immunotherapy
Cyclic Nucleotides
Lymphocytes
Neoplasms
Cyclic GMP
Eating
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immunotherapy with levamisole. Early decrease of cAMP levels in lymphocytes from treated cancer patients. / Lewinski, U. H.; Mavligit, G. M.; Thompson, W. J.; Hersh, Evan M; Ortez, R. A.

In: Cancer, Vol. 44, No. 4, 1979, p. 1280-1283.

Research output: Contribution to journalArticle

Lewinski, U. H. ; Mavligit, G. M. ; Thompson, W. J. ; Hersh, Evan M ; Ortez, R. A. / Immunotherapy with levamisole. Early decrease of cAMP levels in lymphocytes from treated cancer patients. In: Cancer. 1979 ; Vol. 44, No. 4. pp. 1280-1283.
@article{246d74a0512e49b2bc9a574a0021f885,
title = "Immunotherapy with levamisole. Early decrease of cAMP levels in lymphocytes from treated cancer patients",
abstract = "Lymphocyte cyclic nucleotide content was studied before and after Levamisole administration to cancer patients. Twelve patients with disseminated cancer received 100 mg/m 2 on two consecutive days; nine comparable patients with disseminated cancer served as controls. Endogeneous cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) were measured in lymphocytes before, 24, and 48 hours after ingestion of the first dose of Levamisole. A statistically significant decline in lymphocyte cAMP level was observed after drug administration and no significant changes were noted in cGMP levels. Further studies will be necessary to correlate this biochemicl change in cyclic nucleotides with modulation of the functional level of cellular immune mechanisms.",
author = "Lewinski, {U. H.} and Mavligit, {G. M.} and Thompson, {W. J.} and Hersh, {Evan M} and Ortez, {R. A.}",
year = "1979",
doi = "10.1002/1097-0142(197910)44:4<1280::AID-CNCR2820440417>3.0.CO;2-1",
language = "English (US)",
volume = "44",
pages = "1280--1283",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Immunotherapy with levamisole. Early decrease of cAMP levels in lymphocytes from treated cancer patients

AU - Lewinski, U. H.

AU - Mavligit, G. M.

AU - Thompson, W. J.

AU - Hersh, Evan M

AU - Ortez, R. A.

PY - 1979

Y1 - 1979

N2 - Lymphocyte cyclic nucleotide content was studied before and after Levamisole administration to cancer patients. Twelve patients with disseminated cancer received 100 mg/m 2 on two consecutive days; nine comparable patients with disseminated cancer served as controls. Endogeneous cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) were measured in lymphocytes before, 24, and 48 hours after ingestion of the first dose of Levamisole. A statistically significant decline in lymphocyte cAMP level was observed after drug administration and no significant changes were noted in cGMP levels. Further studies will be necessary to correlate this biochemicl change in cyclic nucleotides with modulation of the functional level of cellular immune mechanisms.

AB - Lymphocyte cyclic nucleotide content was studied before and after Levamisole administration to cancer patients. Twelve patients with disseminated cancer received 100 mg/m 2 on two consecutive days; nine comparable patients with disseminated cancer served as controls. Endogeneous cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) were measured in lymphocytes before, 24, and 48 hours after ingestion of the first dose of Levamisole. A statistically significant decline in lymphocyte cAMP level was observed after drug administration and no significant changes were noted in cGMP levels. Further studies will be necessary to correlate this biochemicl change in cyclic nucleotides with modulation of the functional level of cellular immune mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=0018591911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018591911&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197910)44:4<1280::AID-CNCR2820440417>3.0.CO;2-1

DO - 10.1002/1097-0142(197910)44:4<1280::AID-CNCR2820440417>3.0.CO;2-1

M3 - Article

VL - 44

SP - 1280

EP - 1283

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -